The latest achievements of major science and technology projects of "major new drug creation" released by the state: 9 class 1 new drugs approved

On February 22, 2019, the national science and technology special project of "major new drug creation" released the latest achievements After the approval of the National Drug Administration, the new anticancer drug Dabusu supported by the special project will be officially launched after two months of production, providing a new immunotherapy mode for some cancer patients such as Hodgkin's lymphoma Different from surgery, radiotherapy and chemotherapy, dabushu adopts an innovative cancer treatment method - tumor immunotherapy, also known as "biotherapy" Different from the traditional tumor therapy, which focuses on the tumor itself, its mechanism is to enhance the strength of the autoimmune system to fight against tumors, to improve or restore the function of the body's immune system by using drugs, to help immune cells detect and fight against abnormal cancer cells Chinese Medicine Sun Yan, Professor of Cancer Hospital of the Chinese Academy of Sciences and academician of the Chinese Academy of engineering, introduced that the new drug is different from endocrine therapy, chemotherapy and targeted therapy It mobilizes our body's immune cells to attack tumors, so it may be used at the same time with other treatment methods, and the previous focus is that as long as the tumor shrinks, the tumor is relieved, I feel very happy, but What is the current pursuit of immunotherapy? It is not only to cure the patient, but also to make the patient live well When his immune function is restored, he can do well in all aspects Relapsed and refractory Hodgkin's lymphoma is a relatively rare B-cell lymphoma, which occurs in 20-40-year-old young people At present, there is no effective treatment The research shows that the remission rate of relapsed and refractory Hodgkin's lymphoma treated by Dabusu is as high as 80.4%, its efficacy and safety are equivalent to that of imported drugs of the same kind, and the price will be significantly lower than that of imported drugs of the same kind, which provides a new immunotherapy mode for some cancer patients such as Hodgkin's lymphoma This achievement is in the form of cover article in the authoritative medical journal Lancet hematology Publication Yu Dechao, founder of Xinda biology and member of cancer biotherapy Committee of China Anti Cancer Association, said that at present, lymphoma is the main indication in China, which is approved by the state At the same time, the research team is still doing a lot of clinical research on other indications Now, the preliminary curative effects, including lung cancer, liver cancer, gastric cancer, etc., are all doing the clinical phase III Registration test At the same time, the drug has global intellectual property rights, so it is not only listed in China, but also doing clinical research in the world, including the United States According to the outline of the national medium and long term science and technology development plan (2006-2020), China launched and implemented the major science and technology special project of "major new drug creation" in 2008 Since the launch of the special project, more than 1900 projects have been approved, and the central government has invested nearly 20 billion yuan in total, guiding local governments, enterprises and other sources to invest nearly 200 billion yuan Up to now, 38 class 1 new drugs have been released, and an innovation system with various innovation technology platforms as the main body has been initially established, which plays an important role in ensuring and improving people's livelihood, promoting industrial development, supporting medical reform and other aspects Yang Qing, director of the science and Education Department of the national health and Health Commission, said that with the support of the new drug program, China's bio drug innovation capacity continued to increase 2018 is a year of concentrated harvest of special new drugs A total of 9 class 1 new drugs have passed the approval of listing Dabusu has global intellectual property rights, which provides innovative and highly effective treatment mode for cancer patients and improves the accessibility of patients' medication As a special achievement of major new drug development, Dabusu is of great significance in promoting China's independent innovation of anti-cancer drugs to enter the international market competition.